Aarup Kubal, MD
Ophthalmology · Plantation, FLNPI 1780720219
Payments from drug & device makers
Across 608 payments — averaging $290.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$76K
- AbbVie$54K
- Aerie Pharmaceuticals, Inc.$25K
- Alcon$8K
- Sight Sciences, Inc.$2K
- Bausch & Lomb Americas Inc.$2K
- plus $8K from 21 others
Across 1 payment — averaging $88.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$88
What the payments were for
- Speaking & faculty fees$51,63965%
- Travel & lodging$5,8547%
- Food & beverage$20,38426%
- Education$20%
- Gifts$1,4652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 62 | $76,412 |
| AbbVie(2 entities) | 181 | $54,285 |
| Aerie Pharmaceuticals, Inc. | 53 | $25,146 |
| Alcon | 87 | $8,039 |
| Sight Sciences, Inc. | 48 | $2,192 |
| Bausch & Lomb Americas Inc. | 41 | $2,049 |
| Johnson & Johnson Surgical Vision, Inc. | 20 | $1,776 |
| NEW World Medical,inc. | 23 | $1,530 |
| Carl Zeiss Meditec, Inc. | 1 | $1,465 |
| Biotissue Holdings Inc. | 25 | $1,225 |
| Sun Pharmaceutical Industries Inc. | 17 | $436 |
| Amgen(2 entities) | 4 | $405 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $235 |
| Beaver-visitec International, Inc. | 1 | $221 |
| Novartis | 12 | $200 |
| Dompe US, Inc. | 7 | $168 |
| Ivantis, Inc | 1 | $93 |
| Rxsight Inc | 3 | $79 |
| Harrow Eye, LLC | 2 | $75 |
| Oyster Point Pharma, Inc. | 3 | $67 |
| Rayner Intraocular Lenses Limited | 2 | $47 |
| Alcon Research LLC | 2 | $46 |
| Ocular Therapeutix, Inc. | 2 | $42 |
| Mallinckrodt Hospital Products Inc. | 1 | $32 |
| Thea Pharma Inc. | 2 | $29 |
| Akorn, Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$28,803
- Rocklatan$28,160
- Rhopressa$28,035
- CIRRUS photo$1,465
- OMNI(R) SURGICAL SYSTEM (US)$1,183
- Tecnis 1-piece IOL$1,003
- Clareon$941
- Tecnis 3-piece IOL$895
- Tecnis Symfony IOL$895
- Tecnis Symfony Toric IOL$895
- LenSx$656
- SION SURGICAL INSTRUMENT$565
- Centurion$401
- TEPEZZA$384
- Prokera$370
- DURYSTA$343
- MIEBO$267
- ACTIVEFOCUS$252
- AcrySof$233
- Kahook Dual Blade$169
How this compares
$176,334 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 348 | $251,470 |
| LumiganBimatoprost | 223 | $127,890 |
| CombiganBrimonidine Tartrate/Timolol | 218 | $98,150 |
| RhopressaNetarsudil Mesylate | 235 | $94,029 |
| RocklatanNetarsudil Mesylat/Latanoprost | 223 | $90,566 |
| Prednisolone Acetate | 1,382 | $70,253 |
| Alphagan PBrimonidine Tartrate | 82 | $28,335 |
| XiidraLifitegrast | 38 | $25,812 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 153 | $23,962 |
| VyzultaLatanoprostene Bunod | 55 | $23,235 |
| Ketorolac Tromethamine | 722 | $19,546 |
| MoxifloxacinMoxifloxacin Hcl | 844 | $16,726 |
| Travoprost | 91 | $14,856 |
| Brimonidine Tartrate | 424 | $13,498 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 47 | $12,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $54,285 | $505,844871 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $25,146 | $184,595458 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $2,049 | $60,127108 claims |
| AlconSimbrinza, Azopt | $8,039 | $19,14561 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Prolensa | $235 | $9,60852 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $436 | $7,00511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Plantation
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.